title: In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
abstract: The novel 4(th) generation cephalosporin FK037 was in vitro compared to cefepime and cefpirome on 563 multiresistant nosocomial isolates including methicillin-susceptible (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). Their time-kill effect was studied on MSSA, Escherichia coli, Klebsiella pneumoniae, and isolates of Enterobacter cross-resistant to cefotaxime, ceftriaxone, and to ceftazidime, their interaction with amikacin being also evaluated on the latter isolates. Results revealed that FK037 possessed a superior antistaphylococcal activity on MSSA isolates to both other compounds being however equal active to cefepime and cefpirome on multiresistant enterobacteriaceae. Synergy was documented between 4(th) generation cephalosporins and amikacin on K. pneumoniae and on Enterobacter spp. cross-resistant to 3(rd) generation cephalosporins. In the latter species 4(th) generation cephalosporins remained inactive. The presented results support the need of clinical studies with FK037 as monotherapy for nosocomial infections based on the local surveillance data of the level of antimicrobial resistance of each hospital.
authors.affiliation: 1st Department of Propaedeutic Medicine, Greece.
authors.forename: E J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
authors.forename: P
authors.initials: P
authors.lastname: Grecka
authors.forename: A
authors.initials: A
authors.lastname: Tsitsika
authors.forename: C
authors.initials: C
authors.lastname: Tympanidou
authors.forename: H
authors.initials: H
authors.lastname: Giamarellou
mesh_terms: D000150:Acinetobacter / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D000077723:Cefepime; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology*; D004755:Enterobacteriaceae / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D006801:Humans; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011549:Pseudomonas / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D020588:Stenotrophomonas / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D000097572:Cefpirome
chemical_list: D000077723:Cefepime; D015296:Ceftizoxime; D002511:Cephalosporins; D000097572:Cefpirome; C079769:cefoselis